Home
Vaxcyte

Vaxcyte Market Share Analysis for August 2026

Health > Biotechnology and Pharmaceuticals

Domainvaxcyte.com

Year Founded2013

Employees51 - 200

Annual Revenue$25M - $50M

Vaxcyte

Vaxcyte (including company regionals)

vaxcyte.com

See more website traffic and engagement information

Vaxcyte Revenue up to August 2026 is 25M - 50M

revenue generated by Vaxcyte top domains

Vaxcyte top domains revenue over 3 years

Revenue for Vaxcyte top domains

vaxcyte.com25M - 50M

See more with Sales Intelligence

Total visits to Vaxcyte's top domains

Understand Vaxcyte market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

vaxcyte.com10.5K

See more with Sales Intelligence

Avg. visit duration in Vaxcyte's top domains

Analyze Vaxcyte engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

vaxcyte.com00:00:35

See more with Sales Intelligence

Avg. pageviews on Vaxcyte's top domains

See how Vaxcyte keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

vaxcyte.com1.84

See more with Sales Intelligence

Vaxcyte top competitors by domain

Top similar sites in August 2026, ranked by their affinity

pfizer.comCompany NamePfizerEmployees> 10001HQUnited States, New York, New York CityAnnual revenue> $1BTotal visits2MHealth > Biotechnology and Pharmaceuticals

Top technologies used by Vaxcyte

These are the website technologies, by industry, used by Vaxcyte top domains

Advertising (6)

DoubleClick

Marketing (4)

Google Marketing Platform

Widget (4)

Twemoji

Content Management System (3)

WordPress

More Technologies

11

See all

News & Signals from Vaxcyte

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVaxcyte, Inc is developing VAX-31 on Apr 7th '26.Vaxcyte is developing a portfolio of advanced pneumococcal conjugate vaccine (PCV) candidates, including VAX-31, a 31-valent PCV being evaluated in Phase 3 adult and Phase 2 infant clinical trials, and VAX-24, a 24-valent PCV designed to cover more serotypes than any infant PCV currently on the market.

NewsVaxcyte, Inc attended event 25th Annual Needham Virtual Healthcare Conference on Apr 14th '26.SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.

NewsVaxcyte, Inc attended event Guggenheim Emerging Outlook: Biotech Summit on Feb 12th '26.SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.